EGFR and non-small cell lung carcinoma: Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have long been the standard treatment for EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC), the responses to EGFR-TKIs and the duration of treatment are variable.